Richard A. Stewart
Nicole. Thanks,
FDA was vaping with again management, in our of and granting The and productive designation the refinancing hires yet for e-cigarette breakthrough the third cessation SVB therapy or change for Achieve loan. new quarter roles, eventful key
reflects development Achieve to company of rapidly clinical pure-play patients, Much a company. and reflects value transitions shareholders physicians the activity as the more commercially company the a increasing focused this maturing towards from and
the company. the decided commercial acceptance to value that submission, swiftly NDA company approaches the to approval, the and executive a Board expertise enhance M&A management of with strengthen As and as greater Achieve result, future needed
continue exit strategy The the on solely or enhancement, than awe-inspiring assessed with To cytisinicline. and population nicotine a we third-party continues to alone thoughtfully increase. dependence have Achieve to and future big of value value strategic proposition commercialize XX cannot A biotech. a target micro is to carefully more million Americans of pharma, partnering rely let
unpalatable Achieve hold do In to so would fact, for terms. ransom to
from smoking treatment. ability provide strong and first-in-class cessation forward patients move with cessation position a to with our best-in-class of to vaping conviction therapy a a about have strength We
impact health As you profound later, people it the who affect will smoke, a does life has the smoking a family, wider little community. on friends of only expectancy and the and not hear
so on, dementia reverberates respiratory, including cancer, through smoking-related of proliferation cardiovascular, The society. and diabetes, diseases,
$XXX year For and we've of a a treated Nicotine consequences billion it be the nature the nicotine needs to is on ignored long, diseases. too medical such. of cost dependence dependence and disease, smoking-related far the solely focused as of
of up is the XX Achieve has health goal million, our than well-being our plus unique to to of global commitment. population more Americans, privilege the change mission, and dependence X nicotine suffering people millions That disease. wider a and our of from billion
Focusing commercial primary on in enhances we but how exit, execution. combined strategy can not innovative force and digital and it actually Achieve preclude must care no priority, believe sales is longer a with traditional be A possibility. this an accomplish world viable is does the today's
primary care what target are and be potential pharma quitters. challenge restricted? how many grappling when to you efficiently access our do treatment and raise increasingly with. physicians physicians This awareness of big reach will How is currently Our primary new is care option
conversed cost-effective why is innovative been digital has with to Quietly the is Commercial create we experts promoted the for That years importantly working Jaime strategy, and Chief more X develop to commercial scalable. strategy. Jaime to has and Officer. an focused which field dynamic than scenes, highly in and behind a She Xinos
Jaime bag U.S. of roles and to at sales our years pharma Executive so as experience carrying and rep commercial for is Marketing. as can of commercial She has serving the with appropriate, value Abbott, Pfizer. a build Our marketing previously development expand has and XXXX, that global patient and from when since we initially to optimize goal Achieve benefit. VP Novartis growth, nearly XX been
This Medical XXst Achieve's regarding Meeting Officer, dependence, Joint the important views nicotine for smoking the on the stakeholders crucial in held need the their President Chief smoking to meeting cessation With treatments represent smoking for cessation. to Dr. gave Public future cessation and advancing D.C. FDA commitment in to on respect Jacobs, our at treating presented opportunity and Cindy of NIH October
people of immensely than XX% and its extremely who meeting million XX attempt the to adults help who The Approximately health who to crystallized with options nicotine smoke cigarettes successfully. for so annually XX use Nicotine are Americans are quit public U.S. over million limited. and combustible in smoke the importance solutions vape dependence. There of nicotine. doing XX% quit is fewer addictive people providing
XX nearly smoking to peak, with XX% help will revenues its and of and excellent approved, tolerability exceeded want quit is its the millions CHANTIX new $X market. vaping. that cytisinicline people cessation We drug prescription be believe of attributed a If smoking the to years. with first cytisinicline who the efficacy profile U.S. in billion At opportunity to significant
impressive Our endpoint the while trials standard meeting demonstrated clinical FDA Phase III abstinence. continuous of efficacy gold
cytisinicline for for As option cessation. first-in-class cessation poised a to result, is vaping the best-in-class become a option and smoking
Our focus NDA smoking is now acceptance looking the for and cessation. at submission, approval future
to cessation. QX targeting III vaping XXXX clinical are for trial the Phase we commence Additionally,
Cindy the for On an priorities update a ORCA-OL comment status overall FDA her thoughts on launch few participation Jaime NDA and study, recent NDA and the at joint safety and share will today's and NIH timing near-term call, open-label commercial strategy. Then on on readiness will submission provide the meeting.
closing the through to Finally, Jerry returning will before for lead comments. financials us me
turn the I will to call over Cindy. With that,
